XML 53 R43.htm IDEA: XBRL DOCUMENT
v3.22.4

Commitments and Contingent Liabilities (Narrative) (Details) - USD ($) $ in Thousands | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jul. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021
Other Commitments [Line Items] |  |  |
Decsription of occurrence for payments |  | upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand. |
Maximum percentage of payments of royalties (as a percent) |  | 100.00% |
Cumulative Amounts Of Grants Received And Recognized |  | $ 1,227 |
Royality expenses |  | 5,222 | $ 2,590
Bank restricted deposit |  | $ 77 |
Recoverability of VAT amount | $ 1,046 |  |
New Drug Application and Biological License Application [Member] |  |  |
Other Commitments [Line Items] |  |  |
Description of application payment for licensed product |  | $100 thousand upon submission of a New Drug Application (“NDA”), Biological License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug Administration (“FDA”), $100 thousand upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Europe and one hundred thousand dollars upon submission of similar application for each Licensed Product to an equivalent foreign regulatory agency in Asia. Payment in the aggregate shall not be more than $300 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once; |
Royalty payments on sale of product (as a percent) |  | 3.00% |
Capital Additions One [Member] |  |  |
Other Commitments [Line Items] |  |  |
Description of application payment for licensed product |  | $200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once. |

X
- Definition The cumulative amounts of grants received from the IIA and recognized by the company, as of the balance sheet date. + References No definition available. + Details
Name: | cmmb_CumulativeAmountsOfGrantsReceivedAndRecognized
Namespace Prefix: | cmmb_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum percentage of royalties payable on the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR. + References No definition available. + Details
Name: | cmmb_MaximumPercentageOfPaymentsOfRoyalties
Namespace Prefix: | cmmb_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of royalty payments on sale of product developed with funding received from the IIA. + References No definition available. + Details
Name: | cmmb_PercentageOfRoyaltyPaymentsOnSaleOfProduct
Namespace Prefix: | cmmb_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents recoverability of VAT amount. + References No definition available. + Details
Name: | cmmb_RecoverabilityOfVatAmount
Namespace Prefix: | cmmb_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the nature and terms of commitment. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Investments which are not defined as or included in marketable (debt, equity, or other) securities whose use is restricted in whole or in part, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 210 -Section 45 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 210 -Section 50 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581 + Details
Name: | us-gaap_RestrictedInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=cmmb_CapitalAdditionsOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |